scholarly journals Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies

2018 ◽  
Vol 6 (3) ◽  
pp. 197-207 ◽  
Author(s):  
Martin Neovius ◽  
Gustaf Bruze ◽  
Peter Jacobson ◽  
Kajsa Sjöholm ◽  
Kari Johansson ◽  
...  
Author(s):  
Mattias Norrbäck ◽  
Martin Neovius ◽  
Johan Ottosson ◽  
Ingmar Näslund ◽  
Gustaf Bruze

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Francesca Watson ◽  
Maddalena Ardissino ◽  
Ravi J Amin ◽  
Chanpreet Arhi ◽  
Peter Collins ◽  
...  

Introduction: Obesity is an increasingly prevalent global health issue and has a considerable disease burden, including numerous co-morbidities. Atherosclerotic cardiovascular disease (ASCVD) is one such co-morbidity associated with a high mortality rate and prevalence, especially in patients with obesity and concomitant Type 2 diabetes mellitus (T2DM). Bariatric surgery is an effective intervention for patients with obesity, shown to reduce overall cardiovascular disease risk. However, few studies have quantified the long-term impact of bariatric surgery on ASCVD outcomes in the context of key co-morbidities such as T2DM. Hypothesis: Bariatric surgery will improve long-term ASCVD outcomes in obese patients with T2DM. Methods: A nested, nationwide, propensity-matched cohort study was carried out using the Clinical Practice Research Datalink. The study cohort included 593 patients who underwent bariatric surgery and had no past history of ASCVD. A further 593 patients served as propensity-score matched controls. Patients were followed up for a median time of 47.2 months. The primary composite study endpoint was the incidence of ASCVD defined by a diagnosis of new coronary artery disease (CAD), cerebrovascular disease (CeVD), peripheral arterial disease (PAD), or other miscellaneous atherosclerotic disease. Secondary endpoints included all-cause mortality and the incidence of CAD, CeVD, and PAD individually. Results: Patients who underwent bariatric surgery had significantly lower rates of new ASCVD during follow-up (HR 0.53, CI 0.30-0.95, p=0.032). No significant difference was observed in rates of new CAD (HR 0.69, CI 0.32-1.46, p=0.331), CeVD (HR 0.23, CI 0.00-5.45, p=0.1760) and PAD (HR 0.55, CI 0.21-1.43, p=0.218). The bariatric surgery group also had a lower rate of all-cause mortality (HR 0.36, CI 0.19-0.71, p=0.003) compared to controls. Conclusions: In this study, bariatric surgery was associated with improved ASCVD outcomes, as well as lower all-cause mortality, in patients with obesity and T2DM. These findings support the use of bariatric surgery in treating obesity and reducing the burden of its related comorbidities.


2018 ◽  
Vol 29 (1) ◽  
pp. 322-333 ◽  
Author(s):  
Daniel Castaneda ◽  
Violeta B. Popov ◽  
Praneet Wander ◽  
Christopher C. Thompson

Obesity Facts ◽  
2018 ◽  
Vol 11 (2) ◽  
pp. 109-115 ◽  
Author(s):  
Astrid Müller ◽  
Laurence Claes ◽  
Dirk Smits ◽  
Kathrin Schag ◽  
Martina de Zwaan

Sign in / Sign up

Export Citation Format

Share Document